- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
Just after the United States Patent and Trademark Office (USPTO) scrapped a proposed rule that would have prohibited brand drug makers from asserting more patents than necessary on a drug to extend its market exclusivity, Democrats are pushing to include a measure to stop so-called patent thickets to save $1.8 billion in the lame-duck health package they are negotiating with Republicans, sources say.
Advertisement
Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.
Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.
© 2002-2025. Inside Washington Publishers | Contact Us